2025-02-08 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Review

**0) Executive Summary:**

Intuitive Surgical Inc. (ISRG) is a leading developer and manufacturer of robotic-assisted surgery systems.  This report analyzes ISRG's performance, comparing it to the S&P 500 (VOO), and examining its recent financial data and key indicators.

**1) Performance Comparison:**

ISRG has significantly outperformed the S&P 500.  The cumulative return of ISRG is 326.53%, while the S&P 500's cumulative return is 120.63%.  The current difference is 205.9%, placing it at the 92.4th percentile of its historical range relative to the S&P 500 (max difference: 223.6%, min difference: -7.9%).

The provided CAGR data shows consistently high growth rates for ISRG, exceeding 70% in most periods.  Alpha values mostly hover around 0, suggesting performance largely aligned with market trends, except for the 2021-2023 and 2022-2024 periods showing alpha of 1.0 indicating outperformance. The Beta consistently high values between 43.2 to 185.4 implies that ISRG's price is highly sensitive to market movements.

**2) Recent Price Movement:**

* **Closing Price:** $588.5
* **Last Market Price:** $586.03
* **5-Day Moving Average:** $581.90
* **20-Day Moving Average:** $577.21
* **60-Day Moving Average:** $550.76

The stock price is currently slightly below its previous close, showing a minor downward movement. However, all moving averages point towards an upward trend.

**3) Technical Indicators & Expected Return:**

* **RSI:** 52.15  (Slightly above neutral; neither overbought nor oversold)
* **PPO:** -0.166 (Negative value suggests bearish momentum)
* **Delta_Previous_Relative_Divergence:** +1.7 (Short-term upward trend)
* **Expected Return (2+ years):** 20.4% (above S&P 500)

The recent price drop (-$0.42) is not significant enough to constitute a sharp decline.  The combination of indicators shows mixed signals, but the positive expected return and upward-trending moving averages suggest potential for continued growth, despite the negative PPO.

**4) Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|---------------|
| 2024-10-18 | $1.59 | $2.04B        |
| 2024-07-19 | $1.48 | $2.01B        |
| 2024-04-19 | $1.54 | $1.89B        |
| 2023-10-20 | $1.18 | $1.74B        |
| 2023-10-20 | $1.18 | $1.74B        |

There appears to be a duplicate entry for October 2023.  Excluding the duplicate, EPS shows some fluctuation but remains relatively stable, indicating consistent profitability. Revenue has shown a slight upward trend in recent quarters.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |

Revenue is increasing, and profit margins remain consistently high, showing strong financial health.

**Capital and Profitability:**

| Quarter | Equity  | ROE    |
|---------|---------|--------|
| 2024-12-31 | $16.43B | 4.17%  |
| 2024-09-30 | $15.58B | 3.63%  |
| 2024-06-30 | $14.71B | 3.58%  |
| 2024-03-31 | $13.96B | 3.90%  |
| 2023-12-31 | $13.31B | 4.56%  |

Equity is growing, though ROE shows some fluctuation.  Overall, this indicates a healthy financial position.

**6) Overall Analysis:**

ISRG shows a strong track record of outperformance relative to the S&P 500, driven by consistently high growth rates and strong financial fundamentals. While recent technical indicators present a mixed signal, the long-term outlook remains positive, supported by high expected returns, upward-trending moving averages, and consistent revenue growth and high profit margins. However, the high beta value suggests that investors should be mindful of market volatility.  Further investigation into specific drivers of recent price fluctuations would be beneficial.
